OTLK - NASDAQ
Outlook Therapeutics, Inc.
$1.58
-0.94%Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
At a Glance
Live Snapshototlk
Total Current Assets
Last Annual Value
17388.97B
3-Year CAGR
8481%
5-Year CAGR
1475%
10-Year CAGR
372%
Outlook Therapeutics, Inc. Competitors Analysis of Total Current Assets
| Company | Total Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Outlook Therapeutics, Inc. NASDAQ:OTLK | 17388.97B | 8149.0% | 1418.9% | 345.3% | |
 Spruce Biosciences, Inc. NASDAQ:SPRB | 52.11M | -20.1% | -10.7% | N/A | |
 OS Therapies Incorporated NYSE:OSTX | 5.53M | 91.3% | 77.6% | N/A | |
 Century Therapeutics, Inc. NASDAQ:IPSC | 120.77M | -12.0% | -11.9% | N/A | |
 Equillium, Inc. NASDAQ:EQ | 30.28M | -15.0% | -18.3% | N/A | |
 MiNK Therapeutics, Inc. NASDAQ:INKT | 13.85M | 56.7% | -19.0% | N/A | |
 Aligos Therapeutics, Inc. NASDAQ:ALGS | 82.86M | -16.3% | -16.5% | N/A | |
 Relmada Therapeutics, Inc. NASDAQ:RLMD | 93.98M | -1.2% | -15.9% | 43.9% | |
 Sutro Biopharma, Inc. NASDAQ:STRO | 150.93M | -29.0% | -7.1% | 11.8% | |
 CEL-SCI Corporation AMEX:CVM | 6.06M | -4.3% | -33.1% | 0.3% | |
 Cue Biopharma, Inc. NASDAQ:CUE | 36.98M | -10.4% | -11.6% | 9.3% |
Outlook Therapeutics, Inc. Fair Value Envelope
Related Guides
Continue your OTLK research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.